TrademarkOpen
Search / US trademark / 99026957
US trademark / service mark

SOLOSCRIPT

Allowed — statement of use stage
Su - Non-Final Action - Mailed

Status timeline

  1. 3 Feb 2025
    Application filed
    New Application Entered
  2. 14 Jul 2025
    Assigned to an examining attorney
    Assigned To Examiner
  3. 14 Jul 2025
    Office action issued
    Non-Final Action Written
  4. 6 Sep 2025
    Response to office action filed
    Teas Response To Office Action Received
  5. 10 Sep 2025
    Approved for publication
    Approved For Pub - Principal Register
  6. 7 Oct 2025
    Published for opposition
    Published For Opposition
  7. 2 Dec 2025
    Notice of allowance issued — statement of use required
    Noa E-Mailed - Sou Required From Applicant
  8. 8 May 2026
    Statement of use filed
    Teas Statement Of Use Received
  9. 4 Aug 2026
    Office action issued
    Non-Final Action Written
All 22 USPTO events
2026-08-04Non-Final Action Written
2026-08-04Non-Final Action E-Mailed
2026-08-04Notification Of Non-Final Action E-Mailed
2026-07-18Case Assigned To Intent To Use Paralegal
2026-07-18Statement Of Use Processing Complete
2026-05-08Teas Statement Of Use Received
2026-05-08Use Amendment Filed
2025-12-02Noa E-Mailed - Sou Required From Applicant
2025-10-07Published For Opposition
2025-10-07Official Gazette Publication Confirmation E-Mailed
2025-10-01Notification Of Notice Of Publication E-Mailed
2025-09-10Approved For Pub - Principal Register
2025-09-07Teas/Email Correspondence Entered
2025-09-06Teas Response To Office Action Received
2025-09-06Correspondence Received In Law Office
2025-07-14Assigned To Examiner
2025-07-14Non-Final Action Written
2025-07-14Non-Final Action E-Mailed
2025-07-14Notification Of Non-Final Action E-Mailed
2025-07-03New Application Office Supplied Data Entered
2025-02-03New Application Entered
2025-02-03Application Filing Receipt Mailed

Goods & services

Class 1 Chemicals

RNA polymerase in the nature of enzymes for use in the manufacture of pharmaceutical preparations, medical and scientific research, and development of medical treatments; Biotechnology reagents for scientific or medical research use, namely, RNA polymerase and RNA polymerase formulations; Enzymes for use in the preparation and creation of DNA and RNA for use in the manufacture of pharmaceutical preparations, medical and scientific research, and development medical treatments

First use anywhere 26 Sep 2024 · First use in commerce 26 Sep 2024

Class 5 Pharmaceuticals & supplements

Therapeutic RNA, namely, nucleic acid sequences and chemical reagents for medical and veterinary purposes; Reagents for medical or veterinary use

First use anywhere 26 Sep 2024 · First use in commerce 26 Sep 2024

Class 40 Materials treatment

Custom manufacturing of pharmaceuticals; Custom manufacture of therapeutic drugs, in the nature of therapeutics comprising DNA, RNA, genes, and oligonucleotides; Providing custom manufacture of mRNA and long RNA for others, namely, custom synthesis and combinations of mRNA and long RNA molecules; Custom manufacture of oligonucleotides and RNAs for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders

First use anywhere 26 Sep 2024 · First use in commerce 26 Sep 2024

Source & freshness

Source: USPTO Trademark Applications bulk data. This record was last updated by the USPTO file dated 4 Aug 2026; the index was built on 20 Nov 2026 and covers USPTO data through 31 Aug 2026. Open the official USPTO record (TSDR) → If the two differ, the USPTO record is correct.